TRPA1 and psoriasis: Both TRPA1 antagonists (HC030031 and A967079) significantly inhibited spontaneous behaviors (Fig. 8G) when administered immediately (within 30 min) before assessment, suggesting an important role for TRPA1 in mediating cutaneous discomfort in the Aldara model of psoriasis.